WBC Targeting Peptides for Cargo Transport
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for transferring substances, such as nucleic acids and drugs, into cells, particularly white blood cells, face challenges including low efficiency, high cell death rates, and limitations to in vivo applications due to barriers like endosomal membranes and immunogenicity concerns with viral vectors.
Innovation Solution
Development of specific WBC targeting peptides derived from HIV TAT protein, which can efficiently and selectively transport cargo molecules into white blood cells by disrupting endosomal membranes and facilitating receptor-mediated endocytosis, overcoming the limitations of existing delivery methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If general physical or physico-chemical methods (calcium phosphate coprecipitation, electroporation) are used to transfer nucleic acids into cells, then transfer capability is achieved, but transfer efficiency is low and cell death rate is high
Solution Approach 1:
The patent uses a mediator molecule (transporter cargo conjugate) that facilitates the transfer of nucleic acids into cells without direct physical or chemical damage to the cells. The mediator includes a cell-penetrating peptide component that enables efficient cellular uptake while maintaining cell viability, thus resolving the contradiction between achieving transfer and avoiding cell death
Solution Approach 2:
The patent changes the parameters of the transfer system by using a biologically active transporter molecule instead of harsh physical or chemical methods. The transporter cargo conjugate operates under physiological conditions, changing the transfer mechanism from high-energy physical/chemical processes to a biologically compatible process, thereby improving both efficiency and cell survival
2Productivity
If viral vectors are used for gene transfer, then transfer efficiency is improved, but immunogenicity and cytotoxicity increase
Solution Approach 1:
The patent extracts the essential cell-penetrating function from viral vectors by using a synthetic transporter cargo conjugate that mimics the beneficial uptake mechanism without the harmful immunogenic and cytotoxic components. This separates the useful transfer capability from the harmful side effects
Solution Approach 2:
The patent employs a non-viral, synthetic transporter molecule that can be designed and synthesized without the complex biological constraints of viral systems. This disposable-like approach allows for customized, targeted delivery without the persistence and immunogenicity concerns of viral vectors
3Ease of manufacture
If in vitro electroporation or biolistic gene transfer is used, then nucleic acid introduction is achieved, but the methods are not suitable for in vivo applications
Solution Approach 1:
The patent replaces mechanical methods (electroporation, biolistic bombardment) with a biochemical approach using transporter cargo conjugates. This substitution enables the transfer mechanism to function in vivo where mechanical control is not feasible, while maintaining the capability to introduce nucleic acids into cells
4Manufacturing precision
If targeted drug delivery is achieved using antibodies, then cell specificity is improved, but the complexity of the delivery system increases
Solution Approach 1:
The patent merges the targeting function and the cell-penetrating function into a single integrated transporter cargo conjugate molecule. This combination eliminates the need for separate antibody components while maintaining cell specificity, thereby reducing overall system complexity while preserving manufacturing precision
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The WBC targeting peptides enable improved specificity and efficiency in delivering cargo molecules into white blood cells, enhancing therapeutic efficacy while minimizing side effects and immunogenic responses.
Implementation Method 1
disrupting endosomal membranes
Implementation Method 2
facilitating receptor-mediated endocytosis
Data Source
AI summary
The present invention relates to the use of specific transporter cargo conjugate molecules for the transport of a substance of interest (cargo molecule) into white blood cells. Said transporter cargo conjugate molecules may be used for the treatment, prophylaxis, attenuation and/or amelioration of a disease and/or disorder involving white blood cells. The present invention also relates to manufacture of said transporter cargo conjugate molecules, to a method of transporting a substance of interest (cargo) into a white blood cell and to a white blood cell comprising said transporter cargo conjugate molecules or fragments thereof.